Denecimig Biosimilar Bispecific Antibody (Factor IX × Factor X) for Research

Cat No.: GMP-Bios-INN-1157

Anti-F9 therapeutic antibody (Pre-made Denecimig biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Denecimig (development codes Mim8/NN-7769) is a bispecific antibody targeting activated coagulation factor IX and factor X. It is developed by Novo Nordisk and Genmab for hemophilia A. It is in Phase III clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1157-1mg 1mg
GMP-Bios-INN-1157-10mg 10mg
GMP-Bios-INN-1157-100mg 100mg
GMP-Bios-INN-1157-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Denecimig biosimilar, Bispecific mAb, Anti-F9;F10 Antibody: Anti-FIX/P19/PTC/HEMB therapeutic antibody
INN Name Denecimig
Target F9;F10
Format Bispecific mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G4;G4
VD LC Kappa;Kappa
Highest_Clin_Trial (Jan '20) Phase-III
Est. Status Active
100% SI Structure None;7ahu:BA:HL
99% SI Structure 7ahv:AB;None
95-98% SI Structure None;None
Year Proposed 2022
Year Recommended 2023
Companies Genmab;Novo Nordisk
Conditions Approved na
Conditions Active Haemophilia A
Conditions Discontinued na
Production na
Development Tech Human antibody phage display library. Transgenic mice.